13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q2 2017. See the latest, Q3 2026 →

Reported value

$8.75B

+3.1% on the quarter before

Positions

41

4 new, 6 sold out

Top 10

72.1%

of the value

Est. gain

−$130.2M

on stocks held all quarter

Est. return

−1.7%

on those stocks since Q1 2017

Filed

Aug 11, 2017

On SEC EDGAR ↗

Positions as of Jun 30, 2017, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2017. Striped tiles are options.

Cheniere Energy Inc12%
Synchrony Finl10.0%
Viasat Inc10.0%
Colony Northstar Inc7.7%
Allergan Plc6.8%
Qorvo6.5%
Twenty First Centy Fox Inc6.2%
Antero Res Corp5.2%
17 others4.4%
Theravance Biopharma Inc4.2%
Pbf Energy Inc4.0%
Dell Technologies Inc3.9%
Qualcomm3.3%
Twenty First Centy Fox Inc2.3%
Keryx Biopharmaceuticals Inc2.1%
Express Scripts Hldg Co1.9%
Cardinal Health Inc1.8%
Veritiv Corp1.6%
Forward Pharma A/S1.5%
Avis Budget Group1.2%
0.9%
0.8%
0.8%
0.8%
0.7%

Largest buys

Since Q1 2017, sized at quarter-end prices.

  1. Synchrony Finl~$346.8MAdded, 7.1% → 10.0% of the portfolio+11,630,030 shares
  2. Antero Res Corp~$144.0MAdded, 3.9% → 5.2% of the portfolio+6,665,115 shares
  3. Qorvo~$114.9MAdded, 5.8% → 6.5% of the portfolio+1,814,486 shares
  4. Avis Budget Group~$109.1MNew, 0.0% → 1.2% of the portfolio+4,000,000 shares
  5. Express Scripts Hldg Co~$84.8MAdded, 1.0% → 1.9% of the portfolio+1,328,272 shares
  6. Cardinal Health Inc~$77.9MAdded, 1.0% → 1.8% of the portfolio+1,000,000 shares
  7. Silver Run Acquisition~$67.0MNew, 0.0% → 0.8% of the portfolio+6,615,552 shares
  8. Spirit Rlty Cap Inc New~$66.7MNew, 0.0% → 0.8% of the portfolio+9,000,000 shares
  9. Forward Pharma A/S~$16.0MAdded, 1.4% → 1.5% of the portfolio+788,652 shares
  10. Paratek Pharmaceuticals Inc~$8.4MAdded, 0.5% → 0.7% of the portfolio+350,000 shares

Largest sells

Since Q1 2017, sized at quarter-end prices.

  1. Innoviva Inc~$160.1MSold out, 1.9% → 0.0% of the portfolio−11,573,663 shares
  2. Mckesson Corp~$148.3MSold out, 1.7% → 0.0% of the portfolio−1,000,000 shares
  3. Silver Run Acquisition~$69.0MSold out, 0.8% → 0.0% of the portfolio−6,615,554 shares
  4. Liberty Interactive Corp~$65.9MSold out, 0.8% → 0.0% of the portfolio−1,481,719 shares
  5. Cheniere Energy Inc~$48.7MCut, 12.1% → 11.5% of the portfolio−1,000,000 shares
  6. Syngenta Ag~$46.7MSold out, 0.6% → 0.0% of the portfolio−527,968 shares
  7. Amerisourcebergen Corp~$44.5MSold out, 0.5% → 0.0% of the portfolio−502,474 shares
  8. Credit Accep Corp Mich~$37.5MCut, 0.6% → 0.3% of the portfolio−145,700 shares
  9. American Intl Group Inc~$19.1MCut, 0.3% → 0.1% of the portfolio−904,200 shares
  10. Liberty Media Corp Delaware~$16.6MCut, 0.6% → 0.4% of the portfolio−690,528 shares

Holdings

As of Jun 30, 2017; changes in shares since Mar 31, 2017.

Positions, sorted by share of the portfolio
HoldingValue
Cheniere Energy IncCOM NEW · shares −4.6% · price +3.0%11.5%$1.01B+$29.8M
Synchrony FinlCOM · shares +66% · price −13.1%10.0%$873.6M−$79.1M
Viasat IncCOM · shares 0% · price +3.7%10.0%$871.1M+$31.3M
Colony Northstar IncCL A COM · shares 0% · price +9.1%7.7%$675.0M+$56.5M
Allergan PlcSHS · shares 0% · price +1.7%6.8%$591.3M+$10.1M
QorvoCOM · shares +25% · price −7.6%6.5%$569.9M−$37.7M
Twenty First Centy Fox IncCL A · shares 0% · price −12.5%6.2%$542.4M−$77.5M
Antero Res CorpCOM · shares +46% · price −5.3%5.2%$457.5M−$17.4M
Theravance Biopharma IncCOM · shares 0% · price +8.2%4.2%$369.5M+$28.0M
Pbf Energy IncCL A · shares 0% · price +0.4%4.0%$350.0M+$1.4M
Dell Technologies IncCOM CL V · shares 0% · price −4.6%3.9%$345.4M−$16.8M
QualcommCOM · shares 0% · price −3.7%3.3%$288.0M−$11.1M
Twenty First Centy Fox IncCL B · shares 0% · price −12.3%2.3%$202.8M−$28.5M
Keryx Biopharmaceuticals IncCOM · shares 0% · price +17.4%2.1%$186.5M+$27.6M
Express Scripts Hldg CoCOM · shares +108% · price −3.1%1.9%$163.2M−$2.5M
Cardinal Health IncCOM · shares +97% · price −4.5%1.8%$158.2M−$3.7M
Veritiv CorpCOM · shares 0% · price −13.1%1.6%$137.0M−$20.7M
Forward Pharma A/SSPONSORED ADR · shares +14% · price −5.5%1.5%$129.4M−$6.6M
Avis Budget GroupCOM · shares New1.2%$109.1M—
Atara Biotherapeutics IncCOM · shares 0% · price −31.9%0.86%$75.0M−$35.1M
ChipMOS TechnologiesSPONSORED ADR · shares 0% · price +11.4%0.79%$69.4M+$7.1M
Silver Run AcquisitionCOM CL A · shares New0.77%$67.0M—
Spirit Rlty Cap Inc NewCOM · shares New0.76%$66.7M—
Paratek Pharmaceuticals IncCOM · shares +17% · price +25.2%0.66%$57.7M+$9.9M
Gty Technology Holdings IncUNIT 99/99/9999 · shares 0% · price +1.4%0.53%$46.0M+$616,000
Total 41 positions100%$8.75B−$130.2M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q1 2017 to Q2 2017: 35 stocks held throughout, down $130.2M (−1.7%).

  1. Colony Northstar Inc+$56.5M+9%
  2. Viasat Inc+$31.3M+4%
  3. Cheniere Energy Inc+$29.8M+3%
  4. Theravance Biopharma Inc+$28.0M+8%
  5. Keryx Biopharmaceuticals Inc+$27.6M+17%
  6. Twenty First Centy Fox Inc−$28.5M−12%
  7. Atara Biotherapeutics Inc−$35.1M−32%
  8. Qorvo−$37.7M−8%
  9. Twenty First Centy Fox Inc−$77.5M−13%
  10. Synchrony Finl−$79.1M−13%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free